Is Precigen, Inc. (PGEN) A Good Stock To Buy Now?

Key Takeaways

• Papzimeous approved for RRP, targeting 27,000 US patients.
• Drug priced at $460k per four‑dose regimen.
• Forward P/E stands at 9.14, stock trades near $4.
• Potential quarterly revenue beats of 100%‑300% projected for 2026.
• Merck cited as possible acquirer, valuation could reach $20/share.

Pulse Analysis

Precigen’s entry into the commercial arena marks a rare‑disease biotech milestone. Papzimeous, the first FDA‑approved therapy for recurrent respiratory papillomatosis, addresses a niche yet sizable patient pool of about 27,000 in the United States. The $460,000 four‑dose price reflects the high‑cost, high‑value nature of gene‑based treatments and positions the drug among the most expensive therapies on the market. This pricing strategy, combined with a buy‑and‑bill distribution model, creates a revenue stream that can quickly scale once specialist clinics adopt the protocol, but it also introduces reimbursement friction that could temper early sales.

Financially, Precigen trades at roughly $4.02 with a forward price‑to‑earnings multiple of 9.14, suggesting the market has yet to price in the full upside of a commercial launch. Analysts anticipate volatile quarterly results driven by dosing‑based revenue recognition, yet conservative adoption models still project 1,600‑1,700 treated patients in 2026 and nearly 3,000 in 2027. Such volumes could generate revenue surprises that push earnings well above consensus, potentially flipping the company into profitability and expanding the earnings multiple.

Strategically, Precigen’s platform offers acquisition appeal. Large pharmaceutical players, especially Merck, have shown interest in rare‑disease pipelines that can complement their oncology and HPV portfolios. An acquisition could provide a premium valuation—some models estimate up to $20 per share by 2027—while also granting Precigen broader global reach and manufacturing scale. Investors must weigh the upside against execution risks, including insurance coverage, hospital onboarding, and competitive pressures, but the combination of a high‑margin product, strong KOL support, and M&A potential makes Precigen a compelling watch in the biotech sector.